

**TRUSCREEN ANNOUNCES CAPITAL RAISING TO FUND COMMERCIAL OPPORTUNITIES**

Cervical cancer technology company, TruScreen Limited (NZAX:TRU) advises that it is undertaking a capital raising to strengthen its balance sheet and fund commercial growth.

The company, which is well progressed in its commercial realisation pathway, has identified a number of immediate opportunities to drive sales and position the company for continued growth. The new capital will be used to strengthen the balance sheet, fund sales and marketing initiatives, expand manufacturing capabilities and continue improvement to the device's performance.

The capital raising comprises a \$1.5 million Placement to institutional and other select investors at 21 cents per share, which was completed on 31 August 2018 and a Share Purchase Plan (SPP), which will be available to existing retail shareholders of the company, on the same terms and pricing as the Placement. Dates for the SPP will be announced shortly and relevant documents will be sent to shareholders.

TruScreen has the world's only EC certified, real time, objective primary screening device for cervical cancer. The company has made significant progress in the last year and is now reaching a major turning point in its commercial pathway.

Chairman of TruScreen, Mr Robert Hunter, said: "Our company is well progressed in its commercial realisation pathway. There is growing awareness and demand for our TruScreen cervical cancer screening technology; sales are growing rapidly, particularly in China; our new manufacturing facility is now online; and the Board has been refreshed over the last year, with the appointment of new Directors with relevant industry and market knowledge and expertise.

There are a number of immediate commercial opportunities available to us and the capital raise will ensure we have the resources and capacity to progress with these. We are delighted with the support we received for the Placement from our large investors. The SPP will allow our retail shareholders an equal opportunity to participate in this capital raising."

In particular, funds will be used to:

- Expand commercial growth in China, Africa, India and Latin America;
- Fund clinical and familiarisation trials as required for product improvement and acceptance in government programs;
- Expand manufacturing facilities and supply capabilities;
- Build-up inventory; and
- Continued product refinement.

**Placement**

The placement was undertaken with institutional and other select investors subscribing for 7,142,856 shares at 21 cents per share. Settlement and allotment of the new shares is expected to occur on 5 September 2018.

## Share Purchase Plan

Existing retail shareholders of TruScreen will be invited to subscribe for new shares under a Share Purchase Plan. The subscription price will be the same as that for the private placement, being 21 cents per share. The record date for determining entitlements to participate in the Share Purchase Plan and other key dates will be announced shortly.

For questions about this Offer, shareholders should consult their broker, solicitor, accountant, financial adviser, or other professional adviser.

ENDS

For more information visit [www.truscreen.com](http://www.truscreen.com) or contact Martin Dillon, TruScreen Chief Executive Officer, email: [martindillon@truscreen.com](mailto:martindillon@truscreen.com)

## About TruScreen:

TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.

